2025年4月6日 周日
Home > Archive>Volume 25, Issue 9, 2017 >968-972
PDF HTML XML Export Cite reminder
Research progress of osteoprotegerin and atherosclerosis
CSTR:
[cstr]
Author:
Affiliation:

1.School of Clinical Medicine, Weifang Medical University, Weifang, Shandong 261000, China;2.Department of Endocrinology, Weifang People's Hospital, Weifang, Shandong 261000, China)

Clc Number:

R363

  • Article
    • | |
  • Metrics
    • |
  • Reference [41]
    • |
  • Related [20]
    • | | |
  • Comments
    Abstract:

    A soluble glycoprotein, termed osteoprotegerin, is a novel member of the tumor necrosis factor receptor superfamily. Recent studies have shown that osteoprotegerin is not only involved in bone metabolism, but also closely related to energy metabolism in vivo, glycolipid metabolism. And it is closely related to atherosclerosis and glycolipid metabolism disorders, cardiovascular and microvascular diseases. It is not clear that the mechanism is involved in the occurrence and progression of atherosclerosis by regulating glucose and lipid metabolism, endothelial function, inhibiting vascular calcification, inhibiting inflammation, inhibiting apoptosis and so on.

    Reference
    [1] Simonet WS, Lacey DL, Dunstan CR, et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell, 7,9(2):309-319.
    [2] Montagnana M, Lippi G, Danese E, et al.The role of osteoprotegerin in cardiovascular disease.Ann Med, 3,5(3):254-264.
    [3] Baudhuin M, Duplomb L, Teletchea S, et al.Osteoprotegerin:multiple partners for multiple functions.Cytokine Growth Factor Rev, 3,4(5):401-409.
    [4] Bjerre M.Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.Springerplus, 3,2:658.
    [5] Bernardi S, Bossi F, Toffoli B, et al.Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease.Biomed Res Int, 6,6:1752854.
    [6] Ahmed MB, Ismail MI.Relation of osteoprotegerin, visfatin and ghrelin to metabolic syndrome in type 2 diabetic patients.Int J Health Sci (Qassim), 5,9(2):127-139.
    [7] Yu G, Ji X, Jin J, et al.Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy.Ann Clin Biochem, 5,2(2):232-236.
    [8] Fekih O, Triki H, Triki S, et al.Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes.Pediatr Diabetes, 6,8(3):230-236.
    [9] Wang ST, Xu JM, Wang M, et al.Increased plasma osteoprotegerin concentrations in type 1 diabetes with albuminuria.Clin Nephrol, 3,9(3):192-198.
    [10] Xiang GD, Sun HL, Zhao LS.Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.Diabetes Res Clin Pract, 7,6(2):199-206.
    [11] Gordin D, Soro-Paavonen A, Thomas MC, et al.Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes.Diabetes Care, 3,6(7):1 827-833.
    [12] Bortolin RH, Freire Neto FP, Arcaro CA, et al.Anabolic effect of insulin therapy on the bone:osteoprotegerin and osteocalcin up-regulation in streptozotocin-induced diabetic rats.Basic Clin Pharmacol Toxicol, 7,0(3):227-234.
    [13] Pérez de Ciriza C, Moreno M, Restituto P, et al.Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification.Clin Biochem, 4,7(18):272-278.
    [14] Ayina Ayina CN, Sobngwi E, Essouma M, et al.Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity.Diabetol Metab syndr, 5,7:47.
    [15] Ayina Ayina CN, Boudou P, Fidaa I, et al.Osteoprotegerin is not a determinant of metabolic syndrome in sub-Saharan Africans after age adjustment.Ann Endocrinol (Paris), 4,5(3):165-170.
    [16] Bernardi S, Fabris B, Thomas M, et al.Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.Mol Cell Endocrinol, 4,4(1-2):13-20.
    [17] Tavintharan S, Pek LT, Liu JJ, et al.Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.Diab Vasc Dis Res, 4,1(5):359-362.
    [18] 徐美林, 张晓艳, 张超, 等.血清骨保护素与冠状动脉病变程度的关系研究.中华临床医师杂志, 2,3:3 522-525.
    [19] Tousoulis D, Siasos G, Maniatis K, et al.Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.Int J Cardiol, 3,7(5):1 924-928.
    [20] Esteghamati A, Sheikhbahaei S, Hafezi-Nejad N, et al.Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease.Arch Iran Med, 4,7(9):596-601.
    [21] Kiechl S, Schett G, Wenning G, et al.Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease.Circulation, 4,9(18):2 175-180.
    [22] Kwon A, Choi YS, Choi YW, et al.Serum osteoprotegerin is associated with calcified carotid plaque:A strobe-compliant observational study.Medicine, 6,5(15):e3381.
    [23] Morisawa T, Nakagomi A, Kohashi K, et al.Osteoprotegerin is associated with endothelial function and predicts early carotid atherosclerosis in patients with coronary artery disease.Int Heart J, 5,6(6):605-612.
    [24] Wang ST, Zhang CY, Zhang CM.The plasma osteoprotegerin level and osteoprotegerin expression in renal biopsy tissue are increased in type 2 diabetes with nephropathy.Exp Clin Endocrinol Diabetes, 5,3(2):106-111.
    [25] Elsamahy MH, Elhenawy YI.Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria.J Diabetes Complications, 5,9(4):563-567.
    [26] Kuz＇niewski M, Fedak D, Dumnicka P, et al.Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.Adv Med Sci, 6,1(2):269-275.
    [27] Wang HH.Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia.Mod Rheumatol, 5,5(1):123-127.
    [28] 杨伟, 李裕舒, 段卡丹, 等.骨保护素对脐静脉内皮细胞生长的影响.临床心血管病杂志, 0,6(4):307-310.
    [29] Davenport C, Mahmood WA, Forde H, et al.The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.Eur J Endocrinol, 5,3(1):53-61.
    [30] Callegari A, Coons ML, Ricks JL, et al.Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification.Arterioscler Thromb Vasc Biol, 3,3(11):2 491-500.
    [31] Harper E, Forde H, Davenport C, et al.Vascular calcification in type-2 diabetes and cardiovascular disease:Integrative roles for OPG, RANKL and TRAIL.Vasc Pharmacol, 6,2(7):30-40.
    [32] Makarovic＇ S, Makarovic＇ Z, Steiner R, et al.Osteoprotegerin and vascular calcification:clinical and prognostic relevance.Coll Antropol, 5,9(2):461-468.
    [33] Panizo S, Cardus A, Encinas M, et al.RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.Circ Res, 9,4(9):1 041-048.
    [34] Deuell KA, Callegari A, Giachelli CM, et al.RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells:dependence on IL-6 and TNF-α.J Vasc Res, 2,9(6):510-521.
    [35] Kang YH, Jin JS.Long term effect of high glucose and phosphate levels on the OPG/RANK/RANKL/TRAIL system in the progression of vascular calcification in rat aortic smooth muscle cells.Korean J Physiol Pharmacol, 5,9(2):111-118.
    [36] Lane D, Matte I, Laplante C, et al.Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.J Ovarian Res, 3,6:82.
    [37] 徐刚, 高钰琪.骨保护素在心血管疾病发生中的作用及机制研究进展.西南国防医药, 5,5(9):1 030-032.
    [38] Demir P, Erdenen F, Aral H, et al.Serum osteoprotegerin levels related with cardiovascular risk factors in chronic kidney disease.J Clin Lab Anal, 6,0(6):811-817.
    [39] Tintut Y, Patel J, Territo M, et al.Monocyte/macrophage regulation of vascular calcification in vitro.Circulation, 2,5(5):650-655.
    [40] Huang JW, Lien YC, Yang CY, et al.Osteoprotegerin, inflammation and dyslipidemia are associated with abdominal aortic calcification in non-diabetic patients on peritoneal dialysis.Nutr Metab Cardiovasc Dis, 4,4(3):236-242.
    [41] Montagnana M, Lippi G, Danese E.The role of osteoprotegerin in cardiovascular disease.Ann Med, 3,5(3):254-264.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

XU He, LIU Chang-Shan, DOU Jian-Xin. Research progress of osteoprotegerin and atherosclerosis[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2017,25(9):968-972.

Copy
Share
Article Metrics
  • Abstract:936
  • PDF: 732
  • HTML: 0
  • Cited by: 0
History
  • Received:April 10,2017
  • Revised:July 27,2017
  • Online: September 29,2017
Article QR Code

You are the 27991 visitor

Post Code：421001 Fax：0734-8160523

Phone：0734-8160765 E-mail：dmzzbjb@163.net

Editorial Office of Chinese Journal of Arteriosclerosis ® 2025